secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2026-05-07T23:59:59+00:00
Accession:  0001193125-26-210518
Event type: m_and_a
Sentiment:  positive
Materiality: 1.00
Item codes: 1.01, 5.03, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Angelini Pharma to acquire Catalyst Pharma for $4.1B ($31.50/share), premium 28% to VWAP
--------------------------------------------------------------------------------

- All outstanding shares acquired for $31.50 cash per share; total equity value ~$4.1B (21% premium to unaffected close).
- Transaction expected to close Q3 2026, subject to stockholder vote and HSR antitrust clearance.
- Termination fee of ~$155.5M payable by Catalyst under certain conditions; no financing condition.
- Patent litigation with Hetero on FIRDAPSE generic settled; Hetero cannot market before Jan 2035 if approved.
- Directors and executive officers entered voting agreements to support the merger.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312526210518/0001193125-26-210518-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312526210518/d90722d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-210518

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer